Zenas locks down $200M to propel obexelimab through key immunology trials
临床1期引进/卖出临床2期临床3期免疫疗法
Zenas BioPharma on Tuesday announced the completion of an upsized $200 million series C financing that will help move its lead asset obexelimab through a series of mid- and late-stage trials across a range of autoimmune conditions. "This financing enables us to complete multiple potentially value-driving clinical programmes," commented CEO Lonnie Moulder.
The fundraise follows Zenas' $118-million series B in 2022. Proceeds of the latest round will primarily support development of obexelimab, a bifunctional monoclonal antibody designed to inhibit the activity of B-cells, plasmablasts, and CD19-expressing plasma cells involved in autoimmune diseases.
Phase III ongoing
At the forefront is the ongoing Phase III INDIGO trial, which got under way last year to evaluate obexelimab in patients with IgG4-related disease (IgG4-RD). In a mid-stage readout published last August in The Lancet Rheumatology, obexelimab produced "rapid, strong, and sustained" improvement, including complete remission, in most patients with active IgG4-RD.
"Obexelimab's mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B-cell lineage in chronic autoimmune disease and has the potential to show greater clinical benefits, including over a longer course of maintenance treatment," Moulder told FirstWord.
Zenas also plans to start a pair of Phase II studies in multiple sclerosis and systemic lupus erythematosus "within several months," Moulder said. The company has an ongoing Phase II/III trial, dubbed SApHiAre, in warm autoimmune haemolytic anaemia as well. The CEO noted that preliminary results from INDIGO are expected by the end of 2025 and SApHiAre around the end of this year.
Investment from BMS
Bristol Myers Squibb last year struck an agreement to license the experimental bifunctional antibody in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia, making a $50-million upfront payment and an undisclosed equity investment. Obexelimab was originally developed by Xencor before Zenas secured worldwide rights to it in 2021 for up to $480 million.
Beyond obexelimab, Zenas is advancing other autoimmune pipeline candidates including an anti-TNFα antibody ZB002, which is in Phase I, and a preclinical CTLA4-Ig fusion protein dubbed ZB004. "We are considering partnership and collaboration opportunities for these two programmes," Moulder said.
The oversubscribed series C round was co-led by SR One, NEA, Norwest Venture Partners, and Delos Capital. Participation also came from Enavate Sciences and Longitude Capital, as well as new investors including the Federated Hermes Kaufmann Funds and Arrowmark Partners. Existing backers such as Fairmount, Wellington Management, Rock Springs Capital and Vivo Capital maintained their support.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。